Share：
Share this content in WeChat
X
[Chinese][PDF]1681
• Clinical Article •
Value of enhanced T2 star-weighted angiography in the differential diagnosis between benign and malignant renal tumors with T2WI hypo-intensity
LIU Chang  LIU Jinghong  FANG Xin 

Cite this article as: LIU C, LIU J H, FANG X. Value of enhanced T2 star-weighted angiography in the differential diagnosis between benign and malignant renal tumors with T2WI hypo-intensity[J]. Chin J Magn Reson Imaging, 2025, 16(1): 135-139. DOI:10.12015/issn.1674-8034.2025.01.020.


[Abstract] Objective To evaluate the feasibility of enhanced T2 star-weighted angiography (ESWAN) in differentiating diagnosis between benign and malignant renal tumors with T2WI hypo-intensity.Materials and Methods The preoperative MRI data of 145 patients with benign and malignant renal lesions (145 lesions in total, including 112 malignant lesions and 33 benign lesions) confirmed by ESWAN sequence scanning of MR and pathology were collected prospectively. Drawing the region of interest with low signal intensity on T2WI at the level of the largest tumor area. Parameters were compared by Kruskal-Wallis test and Chi-square test. The statistically significant parameters were combined and the model was established by multivariate logistic regression. The receiver operating characteristic (ROC) curve of parameters being statistically different between groups were drawn for identifying benign and malignant renal tumors with T2WI low signal, and the diagnostic efficacies were evaluated.Results There was significant difference between the R2* value and magnitude in diagnosing benign and malignant renal tumors with T2WI hypo-intensity. The area under the ROC curve (AUC) of R2* values was 0.891 [95% confidence interval (CI): 0.829 to 0.937, P < 0.001], with the sensitivity, specificity of 97.3%, 72.7%, respectively. The AUC of magnitude values was 0.869 (95% CI: 0.803 to 0.920, P < 0.001) and the sensitivity, specificity of 86.6%, 81.8%. The AUC of phase values was 0.563 (95% CI: 0.478 to 0.645, P = 0.249), with the sensitivity, specificity of 67.9%, 54.6%. The AUC of combined R2* value and magnitude was 0.886 (95% CI: 0.823 to 0.933, P < 0.001), with the sensitivity, specificity of 97.3%, 72.7%. The AUC of combined R2* value and long axis of lesion was 0.894 (95% CI: 0.832 to 0.939, P < 0.001), with the sensitivity, specificity of 92.0%, 81.8%. The AUC of combined magnitude and long axis of lesion was 0.858 (95% CI: 0.790 to 0.910, P < 0.001), with the sensitivity, specificity of 75.9%, 90.9%.Conclusions The R2* value and combined R2* value and long axis of lesion provide an effective way to discriminate benign from malignant renal tumors with T2WI hypo-intensity and the combined R2* value and long axis of lesion has better diagnostic performance.
[Keywords] kidney diseases；magnetic resonance imaging；enhanced T2 star-weighted angiography；diagnosis；differential

LIU Chang   LIU Jinghong*   FANG Xin  

Department of Radiology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China

Corresponding author: LIU J H, E-mail: liujinghong54@163.com

Conflicts of interest   None.

Received  2024-07-13
Accepted  2025-01-10
DOI: 10.12015/issn.1674-8034.2025.01.020
Cite this article as: LIU C, LIU J H, FANG X. Value of enhanced T2 star-weighted angiography in the differential diagnosis between benign and malignant renal tumors with T2WI hypo-intensity[J]. Chin J Magn Reson Imaging, 2025, 16(1): 135-139. DOI:10.12015/issn.1674-8034.2025.01.020.

[1]
YONG C, STEWART G D, FREZZA C. Oncometabolites in renal cancer[J]. Nat Rev Nephrol, 2020, 16(3): 156-172. DOI: 10.1038/s41581-019-0210-z.
[2]
MSAOUEL P, GENOVESE G, TANNIR N M. Renal cell carcinoma of variant histology: biology and therapies[J]. Hematol Oncol Clin North Am, 2023, 37(5): 977-992. DOI: 10.1016/j.hoc.2023.04.019.
[3]
VAN DER BEEK J N, DE KRIJGER R R, NIEVELSTEIN R A J, et al. MRI characteristics of pediatric and young-adult renal cell carcinoma: a single-center retrospective study and literature review[J/OL]. Cancers, 2023, 15(5): 1401 [2024-11-21]. https://pubmed.ncbi.nlm.nih.gov/36900194/. DOI: 10.3390/cancers15051401.
[4]
CHUNG A, RAMAN S S. Radiologist's disease: imaging for renal cancer[J]. Urol Clin North Am, 2023, 50(2): 161-180. DOI: 10.1016/j.ucl.2023.01.006.
[5]
ZHAO Q X, WU C, TAN S L, et al. Comparing Sonazoid contrast-enhanced ultrasound to contrast-enhanced CT and MRI for differentially diagnosing renal lesions: a prospective multicenter study[J/OL]. World J Urol, 2024, 42(1): 302 [2024-11-21]. https://pubmed.ncbi.nlm.nih.gov/38720010/. DOI: 10.1007/s00345-024-04885-7.
[6]
JIN D D, LIN J H, LI S H, et al. Ultrasound findings and clinical characteristics in differentiating renal urothelial carcinoma from endophytic clear cell renal cell carcinoma[J]. Clin Hemorheol Microcirc, 2024, 88(3): 309-323. DOI: 10.3233/CH-242119.
[7]
DU J, LI K, WANG W, et al. Qualitative and quantitative diagnosis of intramuscular hemangioma subtypes: Diagnostic performance comparison of ESWAN and conventional MRI[J]. Acta Radiol, 2023, 64(1): 208-216. DOI: 10.1177/02841851211065145.
[8]
JHAVERI K S, CLEARY S P, FISCHER S, et al. Blood oxygen level-dependent liver MRI: can it predict microvascular invasion in HCC?[J]. J Magn Reson Imaging, 2013, 37(3): 692-699. DOI: 10.1002/jmri.23858.
[9]
GAO M M, LI S C, YUAN G J, et al. Exploring the value of arterial spin labeling and six diffusion MRI models in differentiating solid benign and malignant renal tumors[J/OL]. Eur Radiol Exp, 2024, 8(1): 135 [2024-11-21]. https://pubmed.ncbi.nlm.nih.gov/39636532/. DOI: 10.1186/s41747-024-00537-y.
[10]
SUN J, XING Z Y, SHA Y Y, et al. Dixon combined with susceptibilityweighted imaging to differentiate the benign and malignant incidental solid masses in the kidney[J]. Chin J CT MRI, 2022, 20(9): 115-117.
[11]
LUO K, ZHANG J G, YU A D, et al. Feasibility study of quantitative susceptibility mapping in the dynamic evaluation of renal ischemia-reperfusion injury in rabbits[J]. J Clin Radiol, 2022, 41(7): 1365-1369. DOI: 10.13437/j.cnki.jcr.2022.07.038.
[12]
LIU R, ZHANG H R, CHENG S J, et al. Association of brain iron overload with brain edema and brain atrophy after intracerebral hemorrhage[J/OL]. Front Neurol, 2020, 11: 602413 [2024-11-21]. https://pubmed.ncbi.nlm.nih.gov/33391165/. DOI: 10.3389/fneur.2020.602413.
[13]
THOMAS G E C, LEYLAND L A, SCHRAG A E, et al. Brain iron deposition is linked with cognitive severity in Parkinson's disease[J]. J Neurol Neurosurg Psychiatry, 2020, 91(4): 418-425. DOI: 10.1136/jnnp-2019-322042.
[14]
ZHANG Y P, NARAYANAN S P, MANNAN R, et al. Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response[J/OL]. Proc Natl Acad Sci USA, 2021, 118(24): e2103240118 [2024-11-21]. https://pubmed.ncbi.nlm.nih.gov/34099557/. DOI: 10.1073/pnas.2103240118.
[15]
CHOUEIRI T K, KAELIN W G. Targeting the HIF2-VEGF axis in renal cell carcinoma[J]. Nat Med, 2020, 26(10): 1519-1530. DOI: 10.1038/s41591-020-1093-z.
[16]
FINLEY L W S. What is cancer metabolism?[J]. Cell, 2023, 186(8): 1670-1688. DOI: 10.1016/j.cell.2023.01.038.
[17]
JIN H R, WANG J, WANG Z J, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics[J/OL]. J Hematol Oncol, 2023, 16(1): 103 [2024-11-21]. https://pubmed.ncbi.nlm.nih.gov/37700339/. DOI: 10.1186/s13045-023-01498-2.
[18]
XIAO Y, YU T J, XU Y, et al. Emerging therapies in cancer metabolism[J]. Cell Metab, 2023, 35(8): 1283-1303. DOI: 10.1016/j.cmet.2023.07.006.
[19]
TIAN S F, LIU A L, LI Y, et al. The value of MR magnetic sensitive technology to identify the cystic renal cell carcinoma and complex renal cysts[J]. Chin J Magn Reson Imag, 2015, 6(10): 762-767. DOI: 10.3969/j.issn.1674-8034.2015.10.009.
[20]
YANG J H, YANG Z X, WU H Z, et al. Quantification of iron deposition in the brain of hypertensive patients using 3D-enhanced susceptibility-weighted angiography (ESWAN)[J/OL]. Curr Med Imaging, 2023 [2024-11-21]. https://pubmed.ncbi.nlm.nih.gov/37366358/. DOI: 10.2174/1573405620666230627112146.
[21]
MENDHIRATTA N, MURAKI P, SISK A E, et al. Papillary renal cell carcinoma: review[J]. Urol Oncol Semin Orig Investig, 2021, 39(6): 327-337. DOI: 10.1016/j.urolonc.2021.04.013.
[22]
ALAGHEHBANDAN R, SIADAT F, TRPKOV K. What's new in the WHO 2022 classification of kidney tumours?[J]. Pathologica, 2022, 115(1): 8-22. DOI: 10.32074/1591-951X-818.
[23]
ÇALıŞKAN S, GÜMRÜKÇÜ G, ÖZSOY E, et al. Renal angiomyolipoma[J]. Rev Assoc Med Bras, 2019, 65(7): 977-981. DOI: 10.1590/1806-9282.65.7.977.
[24]
XU H S, BALCACER P, ZHANG Z, et al. Characterizing T2 Iso- and hypo-intense renal masses on MRI: Can templated algorithms improve accuracy?[J]. Clin Imaging, 2021, 72: 47-54. DOI: 10.1016/j.clinimag.2020.10.051.
[25]
CHENG M, DUZGOL C, KIM T H, et al. Sarcomatoid renal cell carcinoma: MRI features and their association with survival[J/OL]. Cancer Imag, 2023, 23: 16 [2024-11-21]. https://pubmed.ncbi.nlm.nih.gov/36793052/. DOI: 10.1186/s40644-023-00535-0.
[26]
TAKEUCHI M, FROEMMING A T, KAWASHIMA A, et al. Magnetic resonance imaging (MRI) helps differentiate renal cell carcinoma with sarcomatoid differentiation from renal cell carcinoma without sarcomatoid differentiation[J]. Abdom Radiol, 2022, 47(6): 2168-2177. DOI: 10.1007/s00261-022-03501-9.
[27]
HALEFOGLU A M, OZAGARI A A. Comparison of cortico-medullary phase contrast-enhanced MDCT and T2-weighted MR imaging in the histological subtype differentiation of renal cell carcinoma: radiology-pathology correlation[J/OL]. Pol J Radiol, 2021, 86: e583-e593 [2024-11-21]. https://pubmed.ncbi.nlm.nih.gov/34876939/. DOI: 10.5114/pjr.2021.111013.
[28]
BAI X X, ZHANG L O, HUANG L P. Progress and clinical application of magnetic resonance ESWAN imaging technique[J]. J Mod Oncol, 2019, 27(9): 1621-1624. DOI: 10.3969/j.issn.1672-4992.2019.09.037.

PREV The value of CT and MRI features of pancreatic neuroendocrine neoplasm in predicting the pathological grade
NEXT The application value of magnetic resonance image complication sequence combined with ultra-high b-value diffusion-weighted imaging in the diagnosis of parametrial infiltration in cervical cancer
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn